CDK4 and neoplasm: While CDK4/6i plus anti‐PD‐1 and similar combination therapies have shown promise in both preclinical[15, 18, 21] and clinical trials,[22, 23] the anti‐tumor efficacy of sequential targeted therapy followed by immunotherapy has been largely overlooked.